Barclays’s Veracyte VCYT Stock Holding History

Barclays’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$587K	Buy	+10,000	New	+$419K	﹤0.01%	3122

Other funds holding VCYT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Barclays's VCYT Position: Q2 2026 in Review

Barclays reduced its Veracyte (VCYT) stake by 22% in Q2 2026, selling an estimated $270K and leaving 22,623 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2619.

Barclays first reported a position in VCYT in Q4 2013 and has held it in 47 quarters since. The position peaked at $8.91M in Q4 2025. 370 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

Barclays held 22,623 shares of Veracyte worth $1.33M as of Q2 2026.
Barclays sold 6,429 Veracyte shares in Q2 2026, an estimated $270K.
Veracyte made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2619 holding.
Barclays first reported a position in Veracyte in Q4 2013 and has held it in 47 quarters since.
Barclays's Veracyte position peaked at $8.91M in Q4 2025.
370 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.